Karis Bio
2 known investors
Karis Bio develops therapies based on human induced pluripotent stem cells (hiPSCs) to treat cardiovascular diseases, with initial focus on peripheral arterial disease and critical limb ischemia. The company targets vasculogenesis-related conditions such as ischemic heart disease, diabetic retinopathy, diabetic neuropathy, and wound healing.